Methods of detection of circulating melanoma cells: A comparative overview

Cancer Treatment Reviews

Volumn 37, Issue 4, 2011, Pages 284-290

  Nezos, Andrianos ^a   Msaouel, Pavlos ^a   Pissimissis, Nikolaos ^a   Lembessis, Peter ^b   Sourla, Antigone ^b   Armakolas, Athanasios ^a   Gogas, Helen ^a   Stratigos, Alexandros J ^a   Katsambas, Andreas D ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Diagnostic and Therapeutic Medical Center   (Greece)

Author keywords

Circulating melanoma cells; Molecular markers

Indexed keywords

MOLECULAR MARKER;

CANCER GROWTH; CELL ISOLATION; CYTOMETRY; DENSITY GRADIENT CENTRIFUGATION; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; INTERMETHOD COMPARISON; MELANOMA; MELANOMA CELL; METASTASIS; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

HUMANS; MELANOMA; NEOPLASTIC CELLS, CIRCULATING; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953099964     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.10.002     Document Type: Review

References (113)

1. Garbe C., Hauschild A., Volkenandt M., et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma research 2007, 17:393-399.
2. Miller A.J., Mihm M.C. Melanoma. New Engl J Med 2006, 355:51-65.
3. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
4. Palmieri G., Casula M., Sini M.C., Ascierto P.A., Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J C Mol Med 2007, 11:1052-1068.
5. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev 2003, 3:559-570.
6. Taback B., Morton D.L., O'Day S.J., et al. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent results in cancer research Fortschritte der Krebsforschung 2001, 158:78-92.
7. Scoggins C.R., Ross M.I., Reintgen D.S., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006, 24:2849-2857.
8. Quaglino P., Osella-Abate S., Cappello N., et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res 2007, 17:75-82.
9. Mitropapas G., Nezos A., Halapas A., et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clin Chem Lab Med 2006, 44:1403-1409.
10. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metast Rev 2000, 19:193-383. I-XI.
11. Jacob K., Sollier C., Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007, 4:741-756.
12. Koutsilieris M., Laroche B., Thabet M., Thabet M., Fradet Y. The assessment of disease aggressivity in stage D2 prostate cancer patients (review). Anticancer Res 1990, 10:333-336.
13. Mocellin S., Keilholz U., Rossi C.R., Nitti D. Circulating tumor cells: the, leukemic phase' of solid cancers. Trends Mol Med 2006, 12:130-139.
14. Bogdanos J., Karamanolakis D., Tenta R., et al. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr-Relat Cancer 2003, 10:279-289.
15. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol/Hematol 1995, 18:51-64.
16. Koutsilieris M., Bogdanos J., Milathianakis C., et al. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs 2006, 15:795-804.
17. Koutsilieris M., Mitsiades C., Sourla A. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med 2000, 6:251-267.
18. Pantel K., Cote R.J., Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999, 91:1113-1124.
19. Msaouel P., Pissimissis N., Halapas A., Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract & Res 2008, 22:341-355.
20. Xenidis N., Ignatiadis M., Apostolaki S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009, 27:2177-2184.
21. Lembessis P., Msaouel P., Halapas A., et al. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med 2007, 45:1488-1494.
22. Tsouma A., Aggeli C., Pissimissis N., et al. Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res 2008, 28:3945-3960.
23. Panteleakou Z., Lembessis P., Sourla A., et al. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 2009, 15:101-114.
24. Mitsiades C.S., Lembessis P., Sourla A., et al. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 2004, 21:495-505.
25. Ross J.S., Slodkowska E.A. Circulating and disseminated tumor cells in the management of breast cancer. A J Clin Pathol 2009, 132:237-245.
26. Theodoropoulos P.A., Polioudaki H., Agelaki S., et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010, 288:99-106.
27. Ignatiadis M., Kallergi G., Ntoulia M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008, 14:2593-2600.
28. Tolis G., Faure N., Koutsilieris M., et al. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration. J Steroid Biochem 1983, 19:995-998.
29. Winnepenninckx V., Lazar V., Michiels S., et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006, 98:472-482.
30. Hoek K., Rimm D.L., Williams K.R., et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004, 64:5270-5282.
31. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev 2003, 3:453-458.
32. Leiter U., Meier F., Schittek B., Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004, 86:172-178.
33. Gaggioli C., Sahai E. Melanoma invasion - current knowledge and future directions. Pigment Cell Res/sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2007, 20:161-172.
34. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
35. Palmieri G., Ascierto P.A., Perrone F., et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003, 21:767-773.
36. Ghossein R.A., Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer 2000, 36:1681-1694.
37. Fehm T., Solomayer E.F., Meng S., et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005, 7:171-185.
38. Morgan T.M., Lange P.H., Vessella R.L. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 2007, 12:3000-3009.
39. Schittek B., Blaheta H.J., Ellwanger U., Garbe C. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. Recent results in cancer research Fortschritte der Krebsforschung 2001, 158:93-104.
40. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007, 253:180-204.
41. Schittek B., Blaheta H.J., Florchinger G., Sauer B., Garbe C. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. Br J Dermatol 1999, 141:37-43.
42. Muhlbauer M., Langenbach N., Stolz W., et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res 1999, 5:1099-1105.
43. Pachmann K., Clement J.H., Schneider C.P., et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005, 43:617-627.
44. Choesmel V., Anract P., Hoifodt H., Thiery J.P., Blin N. A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases. Cancer 2004, 101:693-703.
45. Keilholz U., Willhauck M., Rimoldi D., et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 1998, 34:750-753.
46. Witzig T.E., Bossy B., Kimlinger T., et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 2002, 8:1085-1091.
47. Okegawa T., Nutahara K., Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol 2008, 180:1342-1347.
48. Molnar B., Ladanyi A., Tanko L., Sreter L., Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001, 7:4080-4085.
49. Ghossein R.A., Carusone L., Bhattacharya S. Molecular detection of micrometastases and circulating tumor cells in melanoma prostatic and breast carcinomas. In Vivo 2000, 14:237-250.
50. Cai Q.Q., Huang H.Q., Lin T.X., Jiang W.Q. Detection and clinical significance of circulating tumor cells in peripheral blood of breast cancer patients. Ai Zheng 2005, 24:837-841.
51. Ulmer A., Schmidt-Kittler O., Fischer J., et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 2004, 10:531-537.
52. Kitago M., Koyanagi K., Nakamura T., et al. MRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem 2009, 55:757-764.
53. Benez A., Geiselhart A., Handgretinger R., Schiebel U., Fierlbeck G. Detection of circulating melanoma cells by immunomagnetic cell sorting. J Clin Lab Anal 1999, 13:229-233.
54. Georgieva J., Milling A., Orfanos C.E., Geilen C.C. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. Melanoma Res 2002, 12:309-317.
55. Loberg R.D., Fridman Y., Pienta B.A., et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 2004, 6:302-309. New York.
56. Ohsie S.J., Sarantopoulos G.P., Cochran A.J., Binder S.W. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008, 35:433-444.
57. Nezos A., Lembessis P., Sourla A., et al. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med 2009, 47:1-11.
58. Medic S., Pearce R.L., Heenan P.J., Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res/sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2007, 20:80-91.
59. Kounalakis N., Goydos J.S. Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management. Curr Oncol Rep 2005, 7:377-382.
60. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
61. Steen S., Nemunaitis J., Fisher T., Kuhn J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proceedings (Baylor University Medical Center) 2008, 21:127-132.
62. Pantel K., Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat Clin Pract 2007, 4:62-63.
63. Szekeres G., Battyani Z. Immuno-diagnosis of malignant melanoma. Magyar onkologia 2003, 47:45-50.
64. Santonocito C., Concolino P., Lavieri M.M., et al. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers. Clin Chim Acta; Int J Clin Chem 2005, 362:85-93.
65. Enk C.D., Lotem M., Gimon Z., Hochberg M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res 2004, 14:361-365.
66. Faye R.S., Aamdal S., Hoifodt H.K., et al. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 2004, 10:4134-4139.
67. Ulmer A., Beutel J., Susskind D., et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 2008, 14:4469-4474.
68. Benez A., Schiebel U., Fierlbeck G. Morphologically intact melanoma cells may be detected in peripheral blood of melanoma patients. Recent results in cancer research Fortschritte der Krebsforschung 2001, 158:113-117.
69. Crowson A.N., Magro C.M., Mihm M.C. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol 2006, 19(Suppl. 2):S71-S87.
70. Winnepenninckx V., Van den Oord J.J. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors. Expert Rev Anticancer Ther 2007, 7:1611-1631.
71. Ugurel S., Utikal J., Becker J.C. Tumor biomarkers in melanoma. Cancer Control 2009, 16:219-224.
72. Carlson J.A., Ross J.S., Slominski A., et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 2005, 52:743-775. quiz 75-8.
73. de Wit N.J., van Muijen G.N., Ruiter D.J. Immunohistochemistry in melanocytic proliferative lesions. Histopathology 2004, 44:517-541.
74. Prichard R.S., Dijkstra B., McDermott E.W., Hill A.D., O'Higgins N.J. The role of molecular staging in malignant melanoma. Eur J Surg Oncol 2003, 29:306-314.
75. Smith B., Selby P., Southgate J., et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 338:1227-1229.
76. Martinez S.R., Hoon D.S. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?. J Cell Biochem 2005, 96:473-483.
77. Vendittelli F., Santonocito C., Paradisi A., et al. A new standardized absolute quantitative RT-PCR method for detection of tyrosinase mRNAs in melanoma patients: technical and operative instructions. Clin Chim Acta; Int J Clin Chem 2009, 409:100-105.
78. Koyanagi K., Kuo C., Nakagawa T., et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005, 51:981-988.
79. Szenajch J., Jasinski B., Synowiec A., et al. Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin Chem 2003, 49:1450-1457.
80. Pantel K., Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Semin Cancer Biol 2001, 11:327-337.
81. de Vries T.J., Fourkour A., Punt C.J., et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Br J Cancer 1999, 80:883-891.
82. Davids V., Kidson S.H., Hanekom G.S. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate. Mol Pathol 2003, 56:43-51.
83. Hoon D.S., Bostick P., Kuo C., et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000, 60:2253-2257.
84. Hoon D.S., Wang Y., Dale P.S., et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995, 13:2109-2116.
85. Reynolds S.R., Albrecht J., Shapiro R.L., et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003, 9:1497-1502.
86. Wascher R.A., Morton D.L., Kuo C., et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003, 21:2558-2563.
87. Keilholz U., Goldin-Lang P., Bechrakis N.E., et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res 2004, 10:1605-1612.
88. Bottoni U., Izzo P., Richetta A., et al. S100 serum level: a tumour marker for metastatic melanoma. Melanoma Res 2003, 13:427-429.
89. Koyanagi K., O'Day S.J., Gonzalez R., et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005, 23:8057-8064.
90. Gogas H., Eggermont A.M., Hauschild A., et al. Biomarkers in melanoma. Ann Oncol 2009, 20(Suppl. 6):vi8-vi13.
91. Rother J., Jones D. Molecular markers of tumor progression in melanoma. Current Genomics 2009, 10:231-239.
92. Bittner M., Meltzer P., Chen Y., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540.
93. Kunz M., Ibrahim S.M., Koczan D., et al. DNA microarray technology and its applications in dermatology. Exp Dermatol 2004, 13:593-606.
94. Mlakar V., Glavac D. DNA microarrays and their use in dermatology. Acta dermatovenerologica Alpina, Panonica, et Adriatica 2007, 16:7-12.
95. Hoek K.S. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Research/sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2007, 20:466-484.
96. Jaeger J., Koczan D., Thiesen H.J., et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007, 13:806-815.
97. Lewis T.B., Robison J.E., Bastien R., et al. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 2005, 104:1678-1686.
98. Hoek K.S., Schlegel N.C., Brafford P., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigm Cell Res/sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2006, 19:290-302.
99. Kuphal S., Bosserhoff A. Recent progress in understanding the pathology of malignant melanoma. Journal Pathol 2009, 219:400-409.
100. Kauffmann A., Rosselli F., Lazar V., et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008, 27:565-573.
101. Koyanagi K., O'Day S.J., Gonzalez R., et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006, 12:1137-1143.
102. Schmidt H., Sorensen B.S., Fode K., Nexo E., Von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res 2005, 15:409-416.
103. Voit C., Kron M., Rademaker J., et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005, 23:1218-1227.
104. Arenberger P., Arenbergerova M., Gkalpakiotis S., et al. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. J Eur Acad Dermatol Venereol 2008, 22:56-64.
105. Takeuchi H., Morton D.L., Kuo C., et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004, 22:2671-2680.
106. Chiang A.C., Massague J. Molecular basis of metastasis. N Engl J Med 2008, 359:2814-2823.
107. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009, 6:339-351.
108. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nature Rev 2007, 7:834-846.
109. Clarke M.F., Fuller M. Stem cells and cancer: two faces of eve. Cell 2006, 124:1111-1115.
110. Trumpp A., Wiestler O.D. Mechanisms of Disease: cancer stem cells-targeting the evil twin. Nat Clin Pract 2008, 5:337-347.
111. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev 2008, 8:755-768.
112. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
113. Fusi A., Ochsenreither S., Busse A., Rietz A., Keilholz U. Stem cell marker nestin expression in peripheral blood of patients with melanoma. Br J Dermatol. 2010.